The purpose of this registry is to observe outcomes of heart transplant recipients who are managed with HeartCare. This is done by collecting information about the participant's heart transplant such as test results, biopsy results, and outcomes, storing that information in a database, and using that information for research. HeartCare is a combination of two tests from one blood draw. One test, AlloMap®, is a well-established test for heart transplant recipients. The other test, AlloSure-Heart, is a new test that directly measures injury of the transplanted heart. HeartCare provides the results of both tests for a noninvasive assessment at time of testing. The registry will be active for up to 5 years after enrollment.
The purpose of this study is to show whether the Barostim Neo system is safe and works in people with heart failure. The device is designed to stimulate the body's natural cardiovascular regulators in your neck to potentially improve your heart failure condition.